神经内分泌肿瘤治疗市场：分析与预测（2022-2028）

全球神经内分泌肿瘤治疗市场规模预计在预测期内增长约 10%。

神经内分泌肿瘤 (NET) 病例数量的增加预计将在预测期内加速对各种治疗方案的需求。 随着新的诊断和治疗方法的发展，该领域正在迅速发展。 高需求的 NET 治疗市场主要是由射频消融和 Ga 标记的放射性核甘酸治疗等检测方法的持续研发工作推动的。

按地区划分，北美市场处于领先地位。 这主要得益于发达的医疗基础设施和众多的医务工作者。 此外，该地区胃神经内分泌肿瘤、肺神经内分泌肿瘤、胰腺神经内分泌肿瘤和类癌数量的增加也推动了市场增长。

本报告调查全球神经内分泌肿瘤治疗市场，定义和概述市场，分析影响市场增长的各种因素、市场规模的变化和预测，以及按各个细分市场/地区/主要国家细分、供需趋势，竞争环境，主要公司概况等。

内容

第一章介绍

第二章调查方法及前提条件

第 3 章市场概述

第 4 章执行摘要

第 5 章 COVID-19：对神经内分泌肿瘤治疗市场的影响

第 6 章神经内分泌肿瘤治疗市场：收益趋势和预测

第 7 章市场洞察：按产品分类

• 生长抑素类似物 (SSA)
• 靶向治疗
• 化疗
• 其他

第 8 章市场洞察：按指示

• 肺
• 胰腺
• 胃肠道
• 其他

第 9 章市场洞察：最终用户

• 医院
• 医务室
• 其他

第 10 章市场洞察：按地区

• 北美
• 欧洲
• 亚太地区
• 其他地区

第 11 章神经内分泌肿瘤治疗市场：市场动态

• 市场驱动力
• 市场问题
• 影响分析

第 12 章神经内分泌肿瘤治疗市场：市场机会

第 13 章神经内分泌肿瘤治疗市场：市场趋势

第14章需求侧与供给侧分析

• 需求方分析
• 供应方分析

第 15 章价值链分析

第 16 章衝突场景

第十七章公司简介

• Pfizer Inc.
• Novartis AG
• Chiasma Inc.
• Ipsen
• Abbvie Inc.
• Valeant Pharmaceuticals International Inc.
• Jubilant Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd
• Advanced Accelerator Applications

第18章 免责事项

The global neuroendocrine tumor treatment market is expected to grow at a significant rate of around 10% during the forecast period. Over the course of the forecast period, an increase in the number of cases of neuroendocrine tumors (NETs) is anticipated to accelerate the demand for various treatment options. As new diagnostics and therapies are developed, this is a rapidly developing field. The demand NET treatment market is primarily driven by ongoing R&D efforts in detection methods like radiofrequency ablation and Ga-labeled radionucleotide therapies.

For instance, Progenics Pharmaceuticals, Inc.'s PSMA Targeted PET Imaging Agent, for instance, is currently in the clinical trial phase and is anticipated to aid in the treatment of prostate cancer. Another important factor driving the expansion of the NET market is the substantial investment in the field made by cancer research organizations and governments worldwide.

Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., and Advanced Accelerator Applications. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst indication, gastrointestinal category to witness robust CAGR during the forecast period"

Based on type, the market is segmented into lungs, pancreas, gastrointestinal, and others. Among them, the gastrointestinal category is to witness the highest CAGR during the forecast period owing to the more number of patients seen for gastric neuroendocrine growths so there is developing prominence and driving this segment.

Moreover, the pancreas portion is supposed to have consistent development during the following couple of years. The expansion of the market is anticipated to be aided by an increase in R&D expenditures for the creation of novel therapies for pancreatic NETs.Pfizer Inc.'s SUNITINIB is being tested in a phase III clinical trial for the treatment of NETs in the pancreas.

"Amongst end-user, the hospitals to hold a significant share in the market in 2020"

On the basis of drive type, the market is categorized into hospitals, clinics, and others. Among these, the hospitals category to hold a significant share of the market in 2020. This is mainly due to these facilities being used for a lot of diagnostic procedures, a large number of patients treated at hospitals, and the availability of trained professionals. The segment's expansion is anticipated to be further bolstered by the availability of numerous NET diagnosis options and developed technologies.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the cardiac monitoring industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and the Rest of World. North American region helped the region to obtain a dominating position in the market. This is mainly due to the well-settled healthcare infrastructure, and availability of medical professionals. Furthermore, rising cases of gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and carcinoid tumors in the region are the propel the growth of the market. For instance, carcinoid tumor affects between 3,000 and 30,000 people in the United States, according to data updated in 2021 by the National Center for Advancing Translational Sciences Genetic and Rare Diseases Information Center. These tumors typically originate in the gastrointestinal tract or the lungs. It is anticipated that the market will expand as a result of the widespread incidence of neuroendocrine cancer in the region.  

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global neuroendocrine tumor treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neuroendocrine Tumor Treatment Market
• 2.2. Research Methodology of the Neuroendocrine Tumor Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROENDOCRINE TUMOR TREATMENT MARKET

6 NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCTS

• 7.1. Somatostatin Analogs (SSAs)
• 7.2. Targeted Therapy
• 7.3. Chemotherapy
• 7.4. Others

8 MARKET INSIGHTS BY INDICATION

• 8.1. Lungs
• 8.2. Pancreas
• 8.3. Gastrointestinal
• 8.4. Others

9 MARKET INSIGHTS BY END USER

• 9.1. Hospitals
• 9.2. Clinics
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROENDOCRINE TUMOR TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROENDOCRINE TUMOR TREATMENT MARKET OPPORTUNITIES

13 NEUROENDOCRINE TUMOR TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Pfizer Inc.
• 17.2. Novartis AG
• 17.3. Chiasma Inc.
• 17.4. Ipsen
• 17.5. Abbvie Inc.
• 17.6. Valeant Pharmaceuticals International Inc.
• 17.7. Jubilant Life Sciences Ltd.
• 17.8. Teva Pharmaceutical Industries Ltd
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Advanced Accelerator Applications

18 DISCLAIMER